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The amount of p27Kip1 establishes a threshold to
which G1 cyclin-cyclin-dependent kinase complexes
must surpass prior to cells progressing into S-phase. The
amount of p27 is greatest in G0 cells, intermediate in G1
cells, and lowest in S-phase cells. However, there is little
known regarding the pathways and mechanisms con-
trolling p27 accumulation in G0 cells. We report that
inhibition of Rho, by either lovastatin or C3 exoenzyme,
can increase the translational efficiency of p27 mRNA.
Similar pharmacologic inhibition of the phosphatidyl-
inositol 3-kinase, the S6 kinase, and the Mek1 kinase
pathways all fail to increase translational efficiency in
MDA468 cells. This Rho-responsive element lies within a
300-nucleotide region at the 3-end of the mRNA. By
supporting the significance of this signaling pathway to
Rho function, we showed that the suppression of RasV12
transformation by RhoAN19 is blocked in p27/ cells. In
contrast this activity is not blocked in Rb/ or p16/
cells. The resistance of p27/ cells to RhoAN19 is not
associated with a failure of RhoAN19 to accumulate to
amounts sufficient to block Rho activity as measured by
the organization of actin stress fibers. Together these
results indicate a link between Rho and p27.
p27 is a member of the Kip family of G1 cyclin-cdk
1 inhibitors
(reviewed in Refs. 1 and 2). In cycling cells, p27 targets cyclin-
cdk2 complexes for inactivation, is associated with cyclin D2/
3-cdk4/6 complexes in a non-inhibitory fashion (3, 4), and is an
assembly factor for cyclin D1-cdk4 complexes (5). Together the
assembly functions and sequestration of p27 in cyclin D-cdk4
complexes can titrate the amount of p27 from cyclin E-cdk2,
allowing cells to progress through G1-phase and enter S-phase
(6). However, because accumulation of p27 is biphasic with a
maximal amount in quiescent non-cycling cells and a lower
intermediate amount in G1 cells, the initial reduction of p27
might be essential for progression from G0 to G1.
Although multiple processes conspire to determine the
threshold amount of p27 at each stage of the cell cycle, includ-
ing regulation at the level of transcription (7–12), protein syn-
thesis (13–15), protein degradation (16, 17), sequestration (4),
and cellular localization (18), the major contributions to the
threshold in G0/G1 cells come from a combination of cdk2-
independent proteolysis (16) and synthesis rate (14). Following
entry into S-phase, p27 levels reach a nadir because of cdk2-
dependent ubiquitin-dependent proteolysis (14). Because p27
abundance is important to the decision to enter and exit the cell
cycle, we expected that the rate of p27 synthesis as cells transit
the G0-G1 period might be a target of mitogenic signals, so we
set out to determine the signaling pathways that control trans-
lation of p27 mRNA.
Here we report that the amount of p27 mRNA translation
was sensitive to the activity of GTPases of the Rho family,
being maximally induced when Rho is inactivated in a G0 cell.
Cell cycle arrest induced by inhibition of either the PI3 or
p70S6 kinase pathways or simply reducing the amount of ac-
tivated Rho or activated Erk without inducing cell cycle arrest
failed to affect the amount of p27 mRNA translation. We have
shown that this aspect of Rho-dependent regulation required
an element within the last 300 nucleotides of the mRNA. We
also established that RhoAN19, a dominant negative allele of
Rho, could inhibit RasV12-induced foci formation in wild-type
cells and cells lacking either Rb or p16 but not those lacking
p27. However, p27 status did not affect the ability of RhoAN19
to interfere with stress fiber formation. Combining these ob-
servations we suggest a model wherein Rho-dependent changes
in p27 synthesis rates may impact progression during the
G0/G1 interval of the cell cycle.
EXPERIMENTAL PROCEDURES
Plasmids—The series of SvL vectors have been described (19). The
expression vectors pCMV-p27 (20), pCEFL-RhoAQ63L and pCEFL-
RhoAN19 (21, 22), and pBabe-Ras V12 (23) have been described.
To generate retroviruses expressing RhoAN19, an N-terminal hemag-
glutinin tag was added by PCR to the cDNA of RhoAN19 from a pCEFL
derivative, and the product was subcloned into pWZL-hygro (23).
Cell Culture, Transfection, and Drug Treatments—MDA468 cells
were grown in Dulbecco’s modified Eagle’s high glucose:F-12 supple-
mented with non-essential amino acids, 10% fetal bovine serum, and 2
mM glutamine. Transient transfections were carried out for MDA468
cells essentially as described (19). Cells were plated at 106 cells per
10-cm dish, grown overnight, and then transfected using the calcium
phosphate method with 5 g of luciferase reporter plasmid, 2.5 g of
pCMV- (CLONTECH), and carrier DNA to a total of 20 g per dish,
unless otherwise stated. Sixteen hours after transfection precipitates
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FIG. 1. Lovastatin induces the translation of p27 mRNA. MDA468 cells were transfected with reporter constructs, and 24 h later they were
treated with either 10 or 50 M PD98059 (PD), LY294002 (LY), 10 or 50 nM rapamycin (RAP), or 30 M lovastatin (LOV) for additional 24 h prior
to analysis. DMS (DMSO), Me2SO. Replicate dishes were used to assess cell cycle distribution (A), efficiency of the treatment on their respective
targets (B), p27 protein accumulation (C), and expression from the reporter plasmids (D and E). A, cell cycle distribution. Samples were analyzed
for DNA content by flow cytometry. The samples are indicated above each panel, and the percent of cells in each phase of the cell cycle for a
representative experiment is shown. The experiment was repeated at least three times for each drug. B, extracts were prepared as described under
“Experimental Procedures” and 40 g resolved by electrophoresis on SDS-polyacrylamide gels (8% for p70S6k and 10% for MAPK and Akt),
transferred to PVDF, and the amount of MAPK, phosphorylated MAPK (phospho-MAPK), p70S6kinase (p70S6K), phosphorylated p70S6kinase
(phospho-p70S6K), and the phosphorylated form of Akt (phospho-Akt) was determined. The treatments are indicated above each lane, and the
respective antibodies used for immunoblotting are to the right of each panel. This experiment was repeated at least three times for each drug. C,
p27 accumulation. Extract was prepared in RIPA buffer and 50 g was resolved by electrophoresis on 12% SDS-polyacrylamide gels, transferred
to PVDF, and probed with a p27-specific antibody. The drug treatment is indicated above each lane. The experiment was repeated at least three
times. D, only lovastatin induces luciferase accumulation from the reporters. Lysates were prepared from transfected cells, and luciferase and
-galactosidase activity was measured as described (19). The experiment was repeated at least three times. E, RNase protection assay analysis.
5 g of total RNA prepared from transfected and drug-treated cells was subjected to RNase protection assay using the probes in the left-hand lane.
Below each lane, we indicate the ratio of luciferase (luc) mRNA to -galactosidase (-gal) mRNA determined by PhosphorImager quantitation. The
experiment was repeated at least three times, and RNA was used at both 5 and 10 g in each case to ensure linearity of the assay.
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were washed out with fresh medium. Where indicated, replicate dishes,
transfected with the same DNA mixtures, were drug-treated 8–10 h
after the washes. Luciferase and -galactosidase activities were as-
sayed 24 or 48 h afterward as described (19) Luciferase activity was
normalized for efficiency (luciferase/-galactosidase ratio) in each
transfection. To calculate the change in expression by each treatment
and construct, we divided the normalized activity in treated cells by the
value obtained in untreated cells, and we expressed this relative to the
change seen in expression from constructs lacking any UTR sequences.
We measured the amount of RNA expressed from each reporter
construct by RNase protection assay as described (19). Quantitation
was performed using an analyzer Fuji Film Bas 2500 and the MacBas
version 2.5 software.
Lovastatin (Merck) was activated as described previously (24). We
obtained PD98059 from Biomol and LY294002 and rapamycin from
Calbiochem. The amount and duration of treatment are indicated in the
legends to the figures.
Cell Cycle Analysis—Cell cycle phase distribution was determined by
flow cytometry of propidium iodide-stained cells. Whole cell suspen-
sions were washed in PBS, fixed in 70% ethanol, stained in 50 g/ml
propidium iodide, 1 mg/ml RNase, 0.1% Triton X-100, and analyzed
using the Multicycle software.
For analysis of transfected populations, an expression vector of the
CD19 surface marker was included in the DNA transfection mixture.
CD19-positive transfected cells were stained as described (25); cells
were detached in PBS, 0.1% EDTA, washed, and stained with a FITC-
conjugated anti-CD19 antibody (BD PharMingen). After fixation in 75%
ethanol, cell pellets were washed in PBS, 1% bovine serum albumin,
0.5% Tween 20 and stained in 5 g/ml propidium iodide, 200 g/ml
RNase, 0.1% Triton X-100. DNA profiles were obtained from the FITC-
positive population.
Immunoblotting—For immunodetection of activated forms of signal-
ing molecules after drug treatments (Fig. 1), cells in the dishes were
washed with ice-cold PBS prior to addition of lysis buffer (50 mM Hepes,
pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 5 mM EGTA, 1.5
mM MgCl2) containing phosphatase and protease inhibitors (20 mM
Na3VO4, 1 mM NaF, 4 mM phenylmethylsulfonyl fluoride, and 10 g/ml
each of aprotinin and leupeptin). Cells were scraped out of the dishes
and incubated for 15 min on ice. Otherwise, cell pellets were lysed in
RIPA buffer (20 mM Hepes, pH 7.4, 100 mM NaCl, 1% Triton X-100, 10%
glycerol, 0.1% SDS, 0.1% deoxycholate) containing protease inhibitors
(4 mM phenylmethylsulfonyl fluoride and 10 g/ml each of aprotinin
and leupeptin) for 15 min on ice and then sonicated. All lysates were
clarified by centrifugation at 13,000  g for 15 min. Protein concentra-
tion was determined by Bradford assay (Bio-Rad). After SDS-PAGE,
proteins were transferred onto PVDF membranes and detected with
antibodies using ECL detection system. The affinity-purified anti-p27
antibody has been described (4). Antibodies are as follows: to MAPK
(06-182, Upstate Biotechnology, Inc.), p70S6k (9202, New England Bio-
labs), phospho-MAPK (9101, New England Biolabs), phospho-Akt
(9271, New England Biolabs), phospho-p70S6k (9204, New England
Biolabs), anti-hemagglutinin epitope (clone 12CA5, Roche Molecular
Biochemicals), and -tubulin (T9026, Sigma).
Foci Formation Assay—Mouse embryo fibroblasts were isolated from
13.5-day post-coitum embryos generated in intercrosses of p27/ (26),
Rb/ (27), or Ink4a/ (28) mice. After harvesting the embryos,
heads and red organs were removed and used for genotyping by both
PCR and Western blot. Carcasses were cut into pieces and then digested
in tyrosine at 37 °C for 30 min. Cell pellets from single embryos were
resuspended in Dulbecco’s modified Eagle’s high glucose medium sup-
plemented with 2 mM glutamine, 10% fetal bovine serum, gentamicin,
penicillin, and streptomycin, plated in a 10-cm dish, and considered as
passage 0. Immortal derivatives were established following a 3T3
protocol.
FIG. 2. The lovastatin response element is in the last 300 nu-
cleotides of the 3-UTR. Cells were transfected with the reporters
indicated below each bar and the accumulation of luciferase, normalized
for -galactosidase, was measured in non-treated (white bars) and lova-
statin-treated cells (black bars). This experiment was repeated five
times, with three independent preparations of plasmid DNA. LOV,
lovastatin.
FIG. 3. Rho activity is a determinant of translation of p27
mRNA as measured by the reporters. A, the accumulation of lucif-
erase from the reporter correlates with changes in Rho activity. The
experiment is similar to that described in the legend to Fig. 1D. Sam-
ples are indicated below each bar. The experiment was performed at
least four times. B, RNase protection assay analysis. RNA was prepared
from cells transfected with either p27 Kip1 or C3 exoenzyme (pEVX) as
indicated above each lane. The amount of total RNA hybridized to the
probes (in the left-hand lane) is indicated above each lane. Below each
lane, we indicate the ratio of luciferase (luc) mRNA to -galactosidase
(-gal) mRNA as determined by PhosphorImager quantitation. RPA
was repeated at least twice for each sample.
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3T3 fibroblasts of different genotypes were plated at 106 cells per
10-cm dish and transfected by the calcium phosphate method with 2 g
of either pBabe-puro or pBabe-RasV12 and 18 g of either pWZL-hygro
or pWZL-RhoN19 per dish. After an overnight incubation, the precipi-
tates were washed out. Cells were grown in complete medium for 24 h
and then selected in the presence of 75 g/ml hygromycin for 4–5 days.
Selected cells were counted, mixed with wild-type primary MEFs (3 
103 drug-resistant cells plus 3  105 wild-type cells), and plated at 3 
105 cells per 60-mm dish. The medium was changed every other day.
After 14 days, foci were stained with Giemsa. Foci were counted on a
Bio-Rad Image Analyzer using the Bio-Rad Quantity One Analysis
Software and confirmed by visual counting under microscope.
RhoN19-expressing MEFs—Retroviral supernatants were generated
by transfection of 293T cells (5  106 cells/10 cm dish) with 15 g of
retroviral vector and 15 g of ecotropic helper virus. Supernatants were
collected 48 h after transfection, pooled from replicate dishes, and
filtered through a 0.45-m filter.
MEFs were plated at 8  105 cells/10-cm dish the night before
infection and exposed to viral supernatants (4 ml per dish) containing 4
g/ml Polybrene for 24 h. Cells were grown in complete medium for 24 h
and then selected in the presence of 75 g/ml hygromycin for 4 days.
Infected MEFs plated in coverslips were fixed in 4% paraformalde-
hyde for 30 min, permeabilized in 1 M Hepes, pH 7.5, 300 mM sucrose,
50 mM NaCl, 3 mM MgCl2, 0.5% Triton X-100 for 4 min on ice, and then
stained with 2 g/ml FITC-phalloidin (Sigma). Counts were performed
on captured images.
RESULTS
A Lovastatin-induced Translational Element Is Contained
within a 300-Nucleotide Sequence at the 3-End of p27
mRNA—To determine whether specific signaling pathways af-
fected the translation of p27 mRNA, we used an assay devel-
oped to measure the translational efficiency of p27 mRNA (19).
This assay takes advantage of a reporter plasmid that ex-
presses the luciferase gene product under the control of the
SV40 promoter, SV40 polyadenylation signal, and the untrans-
lated regions of the p27 mRNA. Following co-transfection of the
reporter vector with a vector expressing -galactosidase from a
cytomegalovirus promoter into MDA468 cells, we treated them
with an assortment of drugs that affected different signaling
pathways. We used an inhibitor of Mek1 (PD98059), an inhib-
itor of PI3 kinase (LY294002) which affects both the activity of
p70S6 kinase and Akt, an inhibitor of p70S6 kinase (rapamy-
cin), or an inhibitor of protein prenylation (lovastatin). As
measured by trypan blue staining the toxicity of these treat-
ments was insignificant (data not shown).
PD98059 had only a modest effect on cell cycle progression,
whereas cells treated with the other drugs accumulated with a
G0/G1 content of DNA (Fig. 1A). We then prepared extracts
from these cells and blotted for Erk1/2, phosphorylated Erk1/2,
p70S6k, phosphorylated p70S6k, phosphorylated Akt, and p27
(Fig. 1B). The amount of phosphorylated Erk1/2 was decreased
in PD98059-treated and lovastatin-treated cells but not in
LY294002- or rapamycin-treated cells. The amount of phospho-
rylated S6 kinase was decreased in rapamycin-, LY294002-,
and lovastatin-treated cells but not in those treated with
PD98059. The amount of phosphorylated Akt was decreased in
LY294002- and lovastatin-treated cells but not in PD98059- or
rapamycin-treated cells. The p27 protein accumulated in cells
treated with lovastatin, rapamycin, or LY294002 but not
PD98059 (Fig. 1C).
Similar to the increase of endogenous p27, lovastatin in-
duced luciferase accumulation (Fig. 1D). Lovastatin is known
to increase the synthesis of p27 (15) and decrease the turnover
of p27 (29). Increased synthesis doubles the available p27, and
the reduction in proteolysis must make up the rest to achieve
the 3–4-fold increase in steady state observed in the treated
cells. Rapamycin and LY294002 did not increase reporter ex-
pression consistent with previous reports (30, 31) that these
agents affect the rate of p27 turnover. The steady state
amounts of luciferase and -galactosidase mRNA were not
differentially affected by the drugs used (Fig. 1D). This suggested
that increased translation of p27 would not be a general effect of
G1 arrest, although an increase in p27 protein might be.
To map the sequences responsible for the lovastatin-depend-
ent induction of p27 synthesis, we examined the effect of lova-
statin treatment on different mutant constructs. Constructs
containing only the 3-UTR alone had negligible activity, con-
sistent with our previous report (19) that the 5-UTR contains
sequences required for both basal and induced translation of
the p27 mRNA. The reporters containing only the 5-UTR were
not affected by lovastatin, suggesting that the 3-UTR was
required for the lovastatin-dependent induction of p27 (Fig. 2).
We found that deleting nucleotides 1680–1978 of the 3-UTR
eliminated the lovastatin-inducible element. This loss was not
due to the length of the 3-UTR because expression from an
even shorter construct lacking two-thirds of the 3-UTR, but
including this 300-nucleotide region (638–1680), was induced
by lovastatin treatment (Fig. 2). The yield of mRNA was equiv-
alent in all the mutants (data not shown). We conclude that the
ability of lovastatin to enhance p27 translation lies in an ele-
ment within the most distal 300 nucleotides of the 3-UTR.
The Lovastatin Effect Is Mediated by Inactivating Rho—
Lovastatin blocks the metabolic pathway leading to protein
prenylation by inhibiting hydroxymethylglutaryl-CoA reduc-
tase. This causes mislocalization of several membrane-an-
chored proteins and can have effect on the activity of Erk, Akt,
and p70S6 kinases as well as other proteins. As the inactiva-
tion of Erk, Akt, and p70S6 kinase did not enhance synthesis
individually (Fig. 1D), we began to look at the Rho family of
GTPases. Because both the Rho proteins, by C-terminal gera-
nylgeranylation, and their GTP exchange factors, by lipid in-
teractions with the pleckstrin homology domain (32), are mem-
brane-localized, lovastatin will block the prenylation of Rho
required for its membrane localization and its subsequent ac-
tivation. Consistent with this, cells treated with lovastatin
showed typical changes in morphology as well as redistribution
of Rho from membranes to the cytosolic fraction (data not
shown).
We examined whether direct inhibition of Rho would en-
hance synthesis from the reporters, similar to the lovastatin-
dependent localization failure. The toxin C3 exoenzyme is a
highly specific inhibitor of RhoA, RhoB, and RhoC that only
weakly affects other GTPases (33). C3 catalyzes ADP-ribosyla-
tion at asparagine 41, preventing interactions of these Rho
family members with their effectors (33). Cells co-transfected
with vectors expressing C3 toxin, a CD19 cell surface marker
expression vector, and the reporters showed increased lucifer-
ase activity similar to lovastatin-treated cells (Fig. 3A). Co-
expression of p27 in place of C3 toxin did not increase reporter
expression (Fig. 3A), despite the fact that both the toxin and
p27 caused growth arrest in the CD19 population of cells
(data not shown). Co-transfection of either C3 or p27 did not
affect the relative amounts of luciferase and -galactosidase
mRNA produced in a manner consistent with the change in
activity (Fig. 3). Together these data indicate that inactivation
of Rho enhances the synthesis of p27.
Next we asked if we could overcome the effect of lovastatin on
reporter expression by using a GTPase-deficient, constitutively
active mutant of RhoA, RhoAQ63L. There is a disagreement in
the literature as to the specific requirements of membrane
localization for activity; however, many groups (34–37) have
shown that constitutively active alleles of Rho act in the ab-
sence of proper membrane localization. This may be attributed
to the overexpression of the mutant, and high levels might
allow it to fulfill some of the activated Rho functions simply by
mass action. We co-transfected RhoAQ63L together with the
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reporter vectors prior to addition of lovastatin. The active form
of Rho prevented the increase in translation caused by treat-
ment with lovastatin (Fig. 3), suggesting that inactivation of
Rho is a required event. This allele does not abrogate the G1
arrest induced by lovastatin (data not shown), indicating that
Rho inactivation is only part of the cellular response to lova-
statin. Additionally, p27/ mouse fibroblasts arrest in re-
sponse to lovastatin, arguing that changes in p27 are only part
of the cellular response to the drug (data not shown). We did
not attempt to ask if the RhoAQ63L allele would reverse the
effect of C3 exoenzyme because ADP-ribosylation would inter-
fere with the ability of the RhoQ63L to associate with effector
proteins. Thus, we concluded that the lovastatin induced in-
crease in reporter synthesis, and the ability of the activated
mutant of Rho to suppress this is consistent with the notion
that Rho could affect p27 accumulation directly, independent of
cyclin E-cdk2-initiated proteolysis as shown previously (38) in
IIC9 cells.
Finally we asked if inhibiting Rho activity would be suffi-
cient to induce p27 synthesis. We were unable to induce syn-
thesis from the reporters when co-transfected with a vector
expressing RhoAN19, a dominant negative mutant of Rho into
MDA468 cells (data not shown). On the other hand, we could
not document that the amount of RhoAN19 expressed was suf-
ficient to inhibit endogenous Rho activity. We next tried
NIH3T3 cells. These cells, unlike MDA468 cells, have a well
organized cytoskeleton with stress fibers easily detected by
phalloidin staining. Stress fiber formation is a reflection of Rho
activity (32). NIH3T3 cells were transfected with RhoAN19 and
reporter activity scored and correlated to the disruption of the
cytoskeleton. Although the cytoskeleton was disrupted, cells
failed to arrest growth, and we failed to observe a change in
reporter activity (data not shown). Consequently, from this and
the data above, we conclude that Rho activity is necessary but
not sufficient in cycling cells to induce changes in p27 synthesis
rate.
Inhibition of Rho Activity Suppresses RasV12-induced Trans-
formation in a p27-dependent Manner—Rho function had been
shown to be necessary for the transforming activity of RasV12
(39–42). Thus we tested if RhoAN19 would interfere with
RasV12 transformation in a p27-dependent manner.
To overcome the Arf/p53-dependent growth arrest that oc-
curs when introducing RasV12 into primary mouse fibroblasts
(28, 43), we immortalized p27-deficient and Rb-deficient cells
by continued passage on a strict 3T3 protocol.2 Additionally, we
used Ink4a/ MEFs, deficient for p16Ink4a (and p19Arf1) (28).
The Arf co-deletion confers immortality. We also used NIH3T3
cells as a prototype model cell line. Most of the 3T3 clones were
still dependent on serum for growth and became quiescent
when grown to confluence (data not shown). There was an
increase in the spontaneous transformation rate of Rb/
cells (Footnote 2 see foci formation in Fig. 4A as an example).
These four lines were co-transfected with retroviral con-
structs encoding RasV12, RhoAN19, both, or the respective
empty vectors, and cells were selected for drug resistance. For
each line, 3,000 resistant cells were pooled and combined with
300,000 wild-type primary mouse fibroblasts and plated into
60-mm dishes. Foci were scored 2 weeks later after Giemsa
staining. The number of foci is representative of the number of
cells transformed by RasV12; they are no longer arrested by
growth to confluence. A representative experiment is shown in
Fig. 4A. In determining the number of foci in Rb/ cells, we
have subtracted the number of colonies arising spontaneously
and suppressed by RhoAN19 co-expression. The extent of trans-
formation by RasV12 was nearly the same in all genotypes, but
colony size was different, with Rb-deficient cells producing
fairly large colonies relative to the Ink4/, p27/, and
NIH3T3 cells (Fig. 4, A and B). Overall, in two independent
experiments with two independent clones of each genotype, we
find that the steady state amount of RasV12 was always lower
in Rb-null cells (Fig. 4C). We do not know why.
Co-expression of RhoAN19 with RasV12 could reduce foci for-
mation in all except for the p27/ cells, where it had no effect
(Fig. 4, A and B). The amount of Rho expressed was equivalent
in all four genotypes (Fig. 4C). Similar Rho-dependent repres-
sion effects on RasV12 were observed in passage 2 fibroblasts
from wild-type and p27/ cells co-transfected with RasV12
and SV40 large T antigen which eliminates both Rb and p53
functions (data not shown). Taken together, these results indi-
cate that the ability of RhoAN19 to interfere with the transform-
ing activity of oncogenic Ras is dependent on the presence of
p27.
Inhibition of Rho Induces Cytoskeletal Changes Independ-
ently of p27 Status—The transformation studies above indicate
that p27, but not Rb or p16, were targets of Rho activity
associated with transformation by RasV12. The ability of p27
deficiency to alter the requirement for Rho signaling might
have reflected a general change in the activity of Rho in these
cells. Stress fibers are a measure of the activity of Rho (32). We
examined the appearance of stress fibers by phalloidin staining
to assess the basal activity of Rho in p27/ cells and cells
expressing the dominant negative mutant. We transduced both
wild-type and p27-deficient passage 2 primary mouse embryo
fibroblasts (MEF) with a retroviral construct expressing
RhoAN19 and a hygromycin resistance gene from a bicistronic
message. Pools of cells were isolated following drug selection.
Because of the selection, cells in these pools were expected to
contain RhoAN19, at levels that would not prevent their prolif-
eration. We confirmed this by measuring thymidine incorpora-
tion during a short pulse and by examining DNA content by
flow cytometry in passage 4 cells (data not shown). Moreover,
we did not detect a significant increase in the steady state
amount of p27, the related cdk inhibitor p21, or cyclin E at
passage four (Fig. 5A). In wild-type cells at passage 4, there
was a small increase (30%) in the synthesis of p27 as measured
by immunoprecipitable material following a 30-min pulse with
[35S]methionine in the presence of LLnL, an inhibitor of the
proteasome (data not shown). The amount of RhoAN19 ex-
pressed was nearly equivalent in the wild-type and p27/
cells, perhaps being a bit higher in the p27/ cells (Fig. 5A).
Stress fibers were readily observed in the control-infected
p27/ cells and clearly disrupted in p27-deficient cells ex-
pressing RhoAN19 (Fig. 5B). These results were quantitated for
500 cells in three independent transductions where control
wild-type fibroblasts expressing RhoAN19 were also examined
(Fig. 5B). As the disruption of actin stress fibers was quanti-
tatively similar, the data suggest that p27-deficient cells do not
have a significantly higher level of basal Rho activity and that
the dominant negative Rho protein can effectively function, at
least with regards to its role in cytoskeleton organization.
DISCUSSION
There is accumulating evidence that G1 progression is im-
pacted by the activation status of Rho family GTPases. Rho has
been linked to transcription of p21 (44), the transcription of
cyclin D1 (45), and perhaps directly to the activation of cyclin
E-cdk2 and the ubiquitin-dependent degradation of p27 (38).
Furthermore, transformation by RasV12 can be suppressed by
dominant negative Rho (40–42), and this at least partially
involves the activation of ROCK (46). Here we show that p27
synthesis can be modulated in a Rho-dependent fashion in2 A. Vidal, S. S. Millard, J. P. Miller, and A. Koff, unpublished data.
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growth-arrested cells, higher in cells with inactive Rho and
lower in cells with active Rho. Additionally, we show that the
suppression of RasV12 transformation by dominant negative
Rho is dependent on p27 but not on either Rb or p16.
Rho and Control of p27 Synthesis—Here we establish that
Rho activity can affect synthesis of p27 in non-cycling cells
through a cis-element contained in the last 300 nucleotides of
the 3-UTR of the mRNA. In breast epithelial cells (above) and
NIH3T3 cells (data not shown), we have shown that inactiva-
tion of the Rho signaling pathway by a generic inhibitor of
protein prenylation (lovastatin) and by a specific inhibitor (C3
exoenzyme) induce synthesis from a p27 reporter without al-
tering the available steady state amount of message from the
reporter. Consistent with the activity of Rho being the target
for lovastatin-induced synthesis, we find that we can overcome
the effect by introducing a constitutively active mutant of Rho,
RhoAQ63L. This mutant cannot efficiently hydrolyze GTP but
can still bind GTP and interact with effectors without the
requirement for membrane localization. Furthermore, other
signaling pathways inactivated by lovastatin, including the
Mek1, PI3-kinase, and S6 kinase pathways, individually can-
not induce synthesis. We did not examine combinatorial effects
and thus cannot state that the lovastatin-induced increase in
synthesis is entirely due to Rho and is not assisted by some
other signaling pathway being modulated (see below).
How might Rho repress translation of the p27 mRNA? There
are many effectors of Rho, ROCK and LIM kinases being the
best defined. Which, if any, of these signaling pathways is
utilized by Rho to repress p27 synthesis needs to be investi-
gated further. We have found that neither cytochalasin D
FIG. 4. RhoN19 inhibits transforma-
tion by RasV12 in a p27-dependent
manner. A, representative experiment
showing foci formation by Giemsa stain-
ing 2 weeks after plating. Populations of
wild-type, Rb null, p16/p19 null, and p27
null mouse embryo fibroblasts were
transfected with the vectors indicated to
the left, selected, and 3,000 of these cells
were plated with 300,000 wild-type MEFs
and grown 14 days prior to staining and
counting of foci. Foci were counted on a
Bio-Rad Image Analyzer using the Bio-
Rad Quantity One Analysis software. B,
the average values of duplicate plates
from at two to three independent experi-
ments are shown in tabular format. C, the
amounts of RasV12 and RhoAN19 were de-
termined by direct immunoblotting of the
selected cells or immunoprecipitation/im-
munoblotting with hemagglutinin anti-
bodies, respectively. This was repeated
twice for each clone.
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which disrupts the cytoskeleton nor plating cycling cells in the
absence of integrin signaling was sufficient to induce p27 re-
porter activity in our assay.2 Because both of these treatments
would affect the activity of the ROCK kinase, this suggests that
the Rho linkage to p27 synthesis may not be associated with
signals that measure cytoskeletal events. Once we narrow
down the sequences required for the Rho-dependent effect on
translation and identify proteins that interact there, in a man-
ner dependent on Rho signaling, we should be able to make
some progress in elucidating this novel translational regulation
pathway of Rho.
Rb and p27 Are on Different Pathways with Respect to Trans-
formation of 3T3 Cells by RasV12—Others have shown that Rho
can increase transcription of cyclin D1 (45) and decrease the
transcription of p21 (44) in various model cell systems. Both
effects are in some fashion dependent on cells with a high
persistent level of Erk signaling. Rho is essential for the re-
pression of p21 transcription in cells that are subject to a
hyperactive Erk signal. Cyclin D1 is induced by such signals
but only when maintained in the presence of Rho activity.
Interestingly, the relationship of cyclin D to cell cycle control is
dependent on the presence of Rb. Established evidence indi-
cates that in the absence of this tumor suppressor, fibroblasts
are no longer dependent on cyclin D-cdk4 activity for cell pro-
liferation (47–49). Consequently, one might have expected that
Rb-negative cells would be refractory to the proliferative effects
of inhibiting Rho. However, we report that the transformation
of Rb/ cells, as well as p16-deficient cells (cells in which a
reduction of the Ink4 inhibitor could increase cyclin D-cdk4
complex formation), was still modulated by the expression of
dominant negative Rho. On the other hand, the transformation
of p27/ cells was not attenuated by the dominant negative
Rho. This could not be attributed to an increase in Rho activity
as measured by the formation of stress fibers in those cells and
their disruption in the cells expressing dominant negative Rho.
There is other supporting evidence for independent functions
for p27 and Rb in transformation. We reported previously (50)
that Rb and p27 could cooperate to enhance tumor development
in a pituitary model independently of enhancement in the
number of proliferating cells. Consequently, Rho is acting
through a mechanism involving p27. This is discrete, although
possibly overlapping, from the p16/Rb axis when participating
in transformation by RasV12.
p27 and p21 in G1 Progression—Singularly, neither p27 nor
p21 has been implicated as an important mediator of G1 pro-
gression in mouse fibroblasts except in the case of NIH3T3 cells
that when treated with antisense oligonucleotides gain a de-
gree of serum independence (51, 52). Primary cultures of p27-
or p21-deficient mouse embryo fibroblasts were not even par-
tially serum-independent (53–55).2 These cells, when immor-
talized, retain serum dependence and are no more prone to
spontaneous transformation as wild-type cells.2 The rate at
which these cells enter S-phase from a serum-starved state is
indistinguishable from wild-type cells. This is similar to obser-
vations in p16 null fibroblasts that have normal growth char-
acteristics and remain susceptible to Ras-induced senescence
(56, 57).
Nevertheless, the notion that p27 is an important protein for
the regulation of the cell cycle during serum-induced entry into
S-phase is supported by the observation that cdk4-deficient
mouse embryo fibroblasts induced to re-enter the cell cycle
from serum starvation have a prolonged G1-phase, a prolonga-
tion that was almost completely eliminated by p27 deficiency.
Similar analysis has not been carried out on p21/ cells. We
have noted that p27 deficiency eliminates a modest delay in
S-phase entry in primary passage 2 mouse fibroblasts express-
ing dominant negative Rho,2 consistent with the possibility
that the G1 function of Rho is affecting accumulation of p27, but
clonal variations in expression level and the resultant delay
make the analysis of this problematic without a good single cell
assay. Rho activity can affect progression of cells from G0 into
S-phase in at least four of the following ways: it can reduce
synthesis of p27 (data here); it can reduce the transcription of
p21 (39); it can increase the transcription of cyclin D1; and it
can affect cyclin E-cdk2 activity. Ultimately, the only thing the
cell needs is to suppress the available p27 (or p21) that can
interact with cyclin E-cdk2. During the G0 to G1 transition, the
amount of p21 in a cell coupled with both cdk2-independent
proteolysis of p27 (16) and a decrease in synthesis of p27 would
establish the threshold to which cyclin D-cdk4 would need to
accumulate. Once cyclin D-cdk4 has passed this threshold,
active cyclin E-cdk2 can accumulate, allowing the cells to pro-
gress from G1 into S-phase and the cdk2-dependent turnover of
p27. In support of the role of Rho suppressing cdk-inhibitor
levels during this transition, we find that p21/ cells are
also resistant to the effect of RhoAN19 in the RasV12 foci forma-
tion assay (data not shown).
Conclusions—In conclusion, our data indicate a genetic re-
lationship between Rho and p27 as related to the ability of Rho
to participate in transformation by RasV12 in immortalized 3T3
cells. It suggests that this is not identical to the function of
inactivating Rb, as Rb-deficient cells retain sensitivity to Rho
inhibition in this assay. We speculate that at least part of the
Rho-p27 connection is associated with modulating the synthe-
sis of p27 protein, because both lovastatin and C3 exoenzyme
increase translational efficiency of p27 mRNA. Nevertheless,
the amount of p27 synthesis is not appreciably increased in
NIH3T3 cells transfected with RhoAN19 at levels sufficient to
disrupt stress fiber formation, indicating that inactivating Rho
while necessary is not sufficient for the translational effect
FIG. 5. RhoN19 alters stress fiber formation in p27/ mouse
embryo fibroblasts. Wild-type (WT) and p27/ mouse embryo fi-
broblasts were transfected with retroviruses encoding a hemagglutinin-
tagged RhoAN19, selected in hygromycin for 4 days, and grown an
additional week prior to making extracts and examining the actin
cytoskeleton by phalloidin staining. A, immunoblots. 50 g of extract
were resolved by 12% SDS-PAGE and transferred to PVDF membranes
and probed with the antibodies indicated to the right of each panel. The
source of extract is indicated above each lane. WZL represents cells
infected by the retrovirus lacking an insert. RhoAN19 represents cells
infected by the WZL retrovirus expressing RhoAN19. This is a repre-
sentative experiment of three independent transductions on three in-
dividual primary cultures. B, RhoAN19 affects stress fiber formation in
a p27-independent manner. Primary mouse fibroblasts were stained
with FITC-phalloidin, and representative fields are shown. The trans-
duced virus is indicated above each field. Four to five fields from three
independent transductions of wild-type and p27/ cells (indicated by
a hatch mark) were used to determine the percentage of cells with stress
fibers, and these results are plotted in the accompanying graph.
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(data not shown). One possibility is that other pathways must
be simultaneously impaired to allow a translational effect of
Rho inactivation. We have tried to co-transfect reporters with
RhoAN19 and either a p27 expression vector or a RasV12 expres-
sion vector, or transfect reporters with RhoAN19 and treat cells
with either LY294002 or rapamycin (data not shown). How-
ever, in no case could we recapitulate the translational en-
hancement we saw with lovastatin or C3 exoenzyme.2 Alterna-
tively, the inability of RhoAN19 to function in translation
enhancement is somehow associated with the fact that it is a
competitive inhibitor of Rho signaling, and both lovastatin and
C3 exoenzyme act in a non-competitive manner. Lovastatin is a
strong inhibitor of prenylation thus affecting both the overall
activity of Rho family members and the activities of many other
molecules involved in the activation of Rho family members. C3
exoenzyme acts catalytically to inactivate the RhoA, RhoB, and
RhoC family members.
However, p27 deficiency can attenuate the ability of RhoAN19
to suppress foci formation. It is important to note that taking
cells co-transfected with RasV12 and RhoAN19, which do not
have enhanced reporter activity (data not shown), is not iden-
tical to the additional selective pressures evident in a foci
formation assay. Only a small proportion (1%) of cells trans-
duced with RasV12 are able to overcome the contact inhibition
growth arrest signal. We do not know why this is, but it could
be related to both the amount of signal a cell needs to become
transformed and the amount that it can tolerate, as well as
additional cryptic mutations that might arise in the population.
It is under this condition where we find the connection between
Rho and p27. How much of that connection is associated with
p27 translation is not yet clear; nevertheless, p27 synthesis is
in some way affected by Rho status, and Rho status is less
important in p27/ cells transformed by RasV12.
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